BRISTOL-MYERS SQUIBB COMPANY

(BMY)
  Report
Delayed Nyse  -  05/18 04:00:02 pm EDT
77.02 USD   -1.53%
07:00aBristol Myers Squibb Data at ASCO and EHA 2022 Highlight Progress in Transforming Treatment for Patients with Cancer and Blood Disorders
BU
05/18Purple Biotech Initiates Phase 2 Study of Combination Treatment for Pancreatic Cancer; Shares Jump
MT
05/18Immatics Initiates Combined Treatment in Solid Tumor Trial
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Bristol Myers Gets Positive CHMP Opinion For Breyanzi in Lymphoma

01/28/2022 | 07:38am EDT

By Michael Dabaie


Bristol Myers Squibb Co. said the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended approval of Breyanzi for adults with diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma and follicular lymphoma grade 3B.

The European Commission will now review the CHMP recommendation. The EC is expected to deliver its final decision within 67 days of receipt of the CHMP opinion. The decision will be applicable to all European Union member states and Iceland, Norway and Liechtenstein.

The CHMP adopted a positive opinion based on results from Transcend NHL 001, a trial of patients with relapsed or refractory LBCL after at least two prior therapies, and additional data from the Transcend World study, the company said.

The studies evaluated patients with R/R DLBCL, PMBCL and FL3B, including those with a broad range of histologies and high-risk disease, and patients who received Breyanzi in the inpatient and outpatient setting.


Write to Michael Dabaie at michael.dabaie@wsj.com


(END) Dow Jones Newswires

01-28-22 0738ET

Stocks mentioned in the article
ChangeLast1st jan.
BRISTOL-MYERS SQUIBB COMPANY -1.53% 77.02 Delayed Quote.23.53%
CORN FUTURES (C) - CBR (FLOOR)/C1 -4.52% 781.25 End-of-day quote.31.69%
All news about BRISTOL-MYERS SQUIBB COMPANY
07:00aBristol Myers Squibb Data at ASCO and EHA 2022 Highlight Progress in Transforming Treat..
BU
05/18Purple Biotech Initiates Phase 2 Study of Combination Treatment for Pancreatic Cancer; ..
MT
05/18Immatics Initiates Combined Treatment in Solid Tumor Trial
MT
05/17Berkshire Hathaway Divests Wells Fargo Stake, Picks Up Citi Shares in Portfolio Reshuff..
MT
05/17Wells Fargo Adjusts Bristol-Myers Squibb's Price Target to $70 from $65, Keeps Equalwei..
MT
05/16Berkshire Hathaway Exited Bristol Myers and AbbVie Stakes in 1Q
DJ
05/16Bristol Myers Squibb Says Phase 3 Trial of Urothelial Cancer Combination Therapy Didn't..
MT
05/16Bristol Myers Squibb Provides Update on CheckMate -901 Trial Evaluating Opdivo (nivolum..
BU
05/16Bristol Myers Squibb Provides Update on Checkmate -901 Trial Evaluating Opdivo Plus Yer..
CI
05/16Bristol Myers Squibb Trial of Carcinoma Treatments Fails to Meet Primary Endpoint
DJ
More news
Analyst Recommendations on BRISTOL-MYERS SQUIBB COMPANY
More recommendations
Financials (USD)
Sales 2022 46 561 M - -
Net income 2022 7 451 M - -
Net Debt 2022 21 743 M - -
P/E ratio 2022 26,7x
Yield 2022 2,79%
Capitalization 164 B 164 B -
EV / Sales 2022 3,99x
EV / Sales 2023 3,61x
Nbr of Employees 32 200
Free-Float 72,8%
Chart BRISTOL-MYERS SQUIBB COMPANY
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQUIBB COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 77,02 $
Average target price 77,98 $
Spread / Average Target 1,24%
EPS Revisions
Managers and Directors
Giovanni Caforio Senior Vice President-US Oncology
David V. Elkins Chief Financial Officer & Executive Vice President
Paul von Autenried Chief Information Officer
Samit Hirawat Chief Medical Officer-Global Drug Development
Rupert J. Vessey Executive VP-Research & Early Development
Sector and Competitors
1st jan.Capi. (M$)
BRISTOL-MYERS SQUIBB COMPANY23.53%163 981
JOHNSON & JOHNSON2.59%461 811
PFIZER, INC.-14.65%282 789
ABBVIE INC.12.58%269 361
ELI LILLY AND COMPANY6.87%265 718
ROCHE HOLDING AG-15.26%264 329